CJC-1295 and Ipamorelin in Animal Growth Hormone Research: What the Published Literature Reports

CJC-1295 and ipamorelin are growth hormone secretagogue-class peptides that appear together in the peer-reviewed literature on emerging peptide supplements, where they have been catalogued alongside BPC-157, TB-500, MK-677, and GHK-Cu as compounds marketed for performance and musculoskeletal recovery despite limited efficacy and safety data [1]. A scoping review conducted according to PRISMA guidelines searched PubMed using permutations of these peptide terms combined with musculoskeletal tissue terms including bone, fracture, muscle, tendon, ligament, meniscus, and cartilage, with two independent reviewers screening each record and a third acting as tiebreaker [1]. The most relevant structural finding for researchers planning work on these peptides is the composition of the evidence base itself. Across the publications identified by that review, 67% used preclinical animal models, most commonly rats [1]. Within those animal models, the review reported that each compound examined — including CJC-1295 and ipamorelin — demonstrated distinct mechanisms with variable effects on tendon, muscle, bone, and ligament healing [1]. These are animal-model observations and are not equivalent to human outcomes. Human investigation of this peptide class was described as limited to a small number of studies, most of which lacked robust controls or rigorous study designs [1]. The human data that did exist were heterogeneous, and the review characterised the observed changes as modest at best, in the domains of metabolic bone health and degenerative knee pain [1]. Substantial heterogeneity in dosing and route of administration across the included studies was identified as a further barrier to synthesis [1]. The review also recorded safety signals within this peptide group. MK-677, a separate secretagogue included in the same review, was associated with significant risks including congestive heart failure [1]. Documented risks reported across the peptide supplement category included cardiovascular complications and metabolic dysfunction such as insulin resistance [1]. The authors concluded that, despite findings in animal studies, the claimed effects of emerging peptide supplements on musculoskeletal recovery and performance remain unsubstantiated by current human trials, and that these compounds should not be treated as a replacement or adjunct for existing orthopaedic standard of care [1]. For investigators, the practical implication is that CJC-1295 and ipamorelin currently sit in a literature where the preclinical animal signal is more developed than the human record, and where the human record is too heterogeneous in design, dose, and route to support quantitative synthesis [1].